Table 1.
Clinical and demographic characteristics of all pre-capillary pulmonary hypertension (PHprecap) patients and between groups.
| Characteristics | All Patients (N = 49) | Survival (N = 39) | Non-Survival (N = 10) | p-Value |
|---|---|---|---|---|
| Age (years) | 58.5 (46.38–70.04) | 58.53 (47.67–70.64) | 55.15 (45.18–68.1) | 0.884 |
| Women/men | 30 (61.2%)/19 (38.8) | 25 (83.3%)/14 (73.7%) | 5 (16.7%)/5 (26.3%) | 0.419 |
| IPAH (n (%)) | 17 (34.7%) | 14 (35.9%) | 3 (33.0%) | 0.363 |
| CTD-PAH (n (%)) | 8 (16.3%) | 4 (10.3%) | 4 (44.0%) | 0.012 |
| Eisenmenger syndrome (n (%)) | 6 (12.8%) | 5 (12.8%) | 1 (10.0%) | 0.404 |
| CTEPH (n (%)) | 14 (28.6%) | 13 (33.3%) | 1 (10.0%) | 0.073 |
| PAH other cause (n (%)) | 4 (8.2%) | 3 (7.7%) | 1 (10.0%) | 0.406 |
| NYHA class 2/3/4 (n (%)) | 11 (22.44)/28 (57.12)/10 (20.4) | 9 (23.04)/25 (64.0)/5 (12.8) | 2 (20.0)/3 (30.0)/5 (50.0) | 0.708 * |
| mPAP (mmHg) | 61.22 ± 18.5 | 61.49 ± 19.1 | 58.75 ± 13.79 | 0.783 |
| 6MWT (m) | 285.0 (217.5–408.0) | 280.0 (240.0–405.0) | 225(170.0–419.0) | 0.69 |
| NT-pro BNP (ng/L) | 1738.0 (469.0–4100.0) | 1472 (398.75–3322.0) | 3683.0 (1902.5–6957.0) | 0.016 |
Definition of abbreviations: IPAH—idiopathic pulmonary arterial hypertension; CTD-PAH—pulmonary hypertension associated with systemic sclerosis; CTEPH—chronic thromboembolic pulmonary hypertension; NYHA—New York Heart Association functional class; mPAP—mean pulmonary artery pressure; 6MWT—six-minute walk test; NT-pro BNP—brain natriuretic peptide. The p-values were determined using the Mann–Whitney U test or chi-square test *. Values are medians (interquartile range) or n (%). * NYHA p = 0.708, degrees of freedom (df) = 2.